Review
Targeted therapy in cervical cancer

https://doi.org/10.1136/esmoopen-2018-000462Get rights and content
Under a Creative Commons license
open access

ABSTRACT

Cervical cancer continues to be a common cancer in women worldwide, especially in less developed regions where advanced stage presentations are common. Addition of bevacizumab to cytotoxic chemotherapy has been the only notable recent advance in the treatment of recurrent and metastatic cervical cancer. Outcomes in patients with locally advanced disease have also plateaued after meaningful gains were achieved with concomitant chemoradiation treatment. Recently, progress has been made in understanding the molecular aberrations in cervical cancer and new therapeutic modalities are emerging, including immune checkpoint inhibitors, therapeutic vaccines, antibody-drug conjugates, and others. In this review we will discuss the data and potential utility of these approaches.

Cervical cancer
targeted therapy

Cited by (0)

Contributors: CV collected the information that was used to write this manuscript. He wrote the first draft of the manuscript. SG conceived the structure and contents of the manuscript, reviewed all versions of the manuscript and undertook the revisions for subsequent drafts.

Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: SG has the following disclosures: Institutional financial interests for conducted research: Roche, Sanofi, Johnson & Johnson, Amgen, Celltrion, Oncosten, Novartis, Intas, Eisai, Biocon. Non-remunerated activities—Advisory board: Roche, Sanofi, Dr. Reddy’s Laboratories, Biocon, Pfizer, Oncosten, Core Diagnostics. Leadership roles: Vice-President of the Indian Society of Medical and Paediatric Oncology. General Secretary of a non-governmental organisation ‘Women’s Cancer Institute—Tata Memorial Hospital’.

Patient consent for publication: Not required.

Provenance and peer review: Not commissioned; externally peer reviewed.